Who is sponsoring NCT03915444?

NCT03915444 is sponsored by HonorHealth Research Institute.

What drugs are being tested in NCT03915444?

Interventions in NCT03915444: nab-Paclitaxel + Cisplatin + Gemcitabine.

What condition does NCT03915444 study?

NCT03915444 studies Pancreatic Ductal Adenocarcinoma.

Is NCT03915444 still recruiting?

NCT03915444 is currently active, enrolled. Last updated 18 April 2023.

Last reviewed 2023-04-18 · How we verify

NCT03915444

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Nab-Paclitaxel + Cisplatin + Gemcitabine in Untreated Metastatic Pancreatic Adenocarcinoma

Active, enrolled Phase 2 Last updated 18 April 2023

What this trial tests

Phase 2 trial testing nab-Paclitaxel + Cisplatin + Gemcitabine in Pancreatic Ductal Adenocarcinoma in 42 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

15 July 2019

Primary endpoint
13 May 2022

31 July 2023

Quick facts

Lead sponsor	HonorHealth Research Institute
Phase	Phase 2
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	42
Start date	15 July 2019
Primary completion	13 May 2022
Estimated completion	31 July 2023
Sites	4 locations across United States

Drugs / interventions tested

nab-Paclitaxel + Cisplatin + Gemcitabine — full drug profile →

Conditions studied

Pancreatic Ductal Adenocarcinoma — all drugs for Pancreatic Ductal Adenocarcinoma →

Sponsor

HonorHealth Research Institute

Who can join

Adults 18 to 105, any sex, with Pancreatic Ductal Adenocarcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a phase II open-label study evaluating the efficacy and safety of nab-paclitaxel cisplatin, and gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Systemic Therapy of Metastatic Pancreatic Adenocarcinoma: Current Status, Challenges, and Opportunities.
Chakrabarti S, Kamgar M, Mahipal A. · · 2022 · cited 17× · PMID 35681565 · DOI 10.3390/cancers14112588
Overcoming the Tumor Microenvironmental Barriers of Pancreatic Ductal Adenocarcinomas for Achieving Better Treatment Outcomes.
Alzhrani R, Alsaab HO, Vanamal K, Bhise K, et al · · 2021 · cited 13× · PMID 34212073 · DOI 10.1002/adtp.202000262
Nanomedicine for cancer patient-centered care.
Sorrentino C, Ciummo SL, Fieni C, Di Carlo E. · · 2024 · cited 10× · PMID 39434967 · DOI 10.1002/mco2.767
Phase IB trial of high dose ascorbic acid + nab-paclitaxel + cisplatin + gemcitabine in patients with untreated metastatic pancreatic cancer.
Jameson GS, LeGrand SD, Gordon MS, Roe DJ, et al · · 2025 · PMID 41197185 · DOI 10.1016/j.redox.2025.103895
Phase II clinical trial of nab‐paclitaxel plus cisplatin plus gemcitabine (NABPLAGEM) in patients with untreated advanced pancreatic cancer
Jameson G, Hosein P, Pierce E, Kamgar M, et al · · 2024

Verify or expand the search:

Other recruiting trials for Pancreatic Ductal Adenocarcinoma

Currently open trials in the same condition.

NCT07324096 — A Screening Program to Improve the Early Detection of Sporadic Pancreatic Cancer in Individuals With a High-Risk of Deve · NA · recruiting
NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
NCT07328607 — Outcomes After Laparoscopic Versus Open Pancreaticoduodenectomy · NA · recruiting
NCT07232810 — Prognostic Outcomes of Total Mesopancreas Excision for Pancreatic Head Cancer · NA · recruiting
NCT07261631 — Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors · Phase 1 · recruiting

Other HonorHealth Research Institute trials

Trials by the same sponsor.

NCT05229588 — Lurbinectedin in Patients With Advanced Gastrointestinal Malignancies With DNA Repair Mutations · Phase 2 · completed
NCT05216120 — Pemigatinib in Subjects With Adenosquamous Carcinoma of the Pancreas · Phase 2 · withdrawn
NCT05004025 — Single Arm Trial of Tumor-Treating Fields in Combination With Nivolumab and Ipilimumab in Metastatic Uveal Melanoma · Phase 1 · completed
NCT04611139 — Pilot Trial of SP-2577 Plus Pembrolizumab in Select Gynecologic Cancers · Phase 1 · withdrawn
NCT05175521 — Inhaled IAV vs Inhaled Eucalyptus for the Treatment of Nausea With Acute Migraine · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03915444 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by HonorHealth Research Institute
Last refreshed: 18 April 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03915444.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing